Computational techniques for three-dimensional reconstruction and multi-labeling of serially sectioned tissue
US-2025139765-A1 · May 1, 2025 · US
US12579645B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12579645-B2 |
| Application number | US-202318451507-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 17, 2023 |
| Priority date | Aug 18, 2022 |
| Publication date | Mar 17, 2026 |
| Grant date | Mar 17, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Systems and methods are described herein for processing electronic medical images to predict a biomarker's presence, including receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient. A machine learning system may determine a biomarker expression level prediction for the one or more digital medical images. The biomarker expression level prediction may be based on a determined transcriptomic score and protein expression score for the one or more digital medical images. A slide overlay indicating a region of tissue on the one or more digital medical images that is most likely to contribute to the slide level biomarker expression prediction may be generated.
Opening claim text (preview).
What is claimed is: 1 . A computer-implemented method for processing electronic medical images to predict a biomarker's presence, comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic score including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 2 . The method of claim 1 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 3 . The method of claim 2 , wherein the one or more salient regions correspond to cancerous tissue. 4 . The method of claim 1 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 5 . The method of claim 1 , wherein the biomarker expression is human epidermal growth factor receptor 2. 6 . The method of claim 1 , wherein the biomarker expression level prediction is performed upon determining that the received one or more slides has a immunohistochemistry (IHC) score of IHC-0 or IHC-1. 7 . The method of claim 1 , wherein the predetermined value of ERBB2 mRNA is 7.6. 8 . The method of claim 1 , wherein generating a slide overlay includes generating a tissue map overlay and/or a heatmap overlay. 9 . A system for processing electronic medical images, the system comprising: at least one memory storing instructions; and at least one processor configured to execute the instructions to perform operations comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic score including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 10 . The system of claim 9 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 11 . The system of claim 10 , wherein the one or more salient regions correspond to cancerous tissue. 12 . The system of claim 9 , wherein the biomarker expression level prediction is performed upon determining that the received one or more slides has a immunohistochemistry (IHC) score of IHC-0 or IHC-1. 13 . The system of claim 9 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 14 . The system of claim 9 , wherein the predetermined value is predetermined value of ERBB2 mRNA is 7.6. 15 . A non-transitory computer-readable medium storing instructions that, when executed by a processor, perform operations processing electronic medical images, the operations comprising: receiving one or more digital medical images, the one or more digital medical images being of at least one pathology specimen associated with a patient; determining a protein expression score for the one or more digital medical images, the protein expression score including an immunohistochemistry (IHC) score for each of the one or more digital medical images; determining a transcriptomic including a level of Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) mRNA; determining, by a machine learning system, a biomarker expression level prediction for the one or more digital medical images, the biomarker expression level prediction being based on the transcriptomic score and the protein expression score for the one or more digital medical images, wherein the biomarker expression level prediction is determined to be a true absence of human epidermal growth factor receptor 2 (HER2) expression upon determining that the immunohistochemistry score is IHC-0+, indeterminate, or equivocal-IHC-1+ and that the ERBB2 mRNA level is less than a predetermined value; and generating a slide overlay indicating a region of tissue on the one or more digital medical images that contributes to the biomarker expression level prediction. 16 . The non-transitory computer-readable medium of claim 15 , further comprising: determining, salient regions of the received one or more digital medical images prior to determining the biomarker expression level, wherein non-salient image regions are excluded from subsequent processing. 17 . The non-transitory computer-readable medium of claim 16 , wherein the one or more salient regions correspond to cancerous tissue. 18 . The non-transitory computer-readable medium of claim 15 , wherein the one or more digital medical images are images of breast tissue stained with hematoxylin and eosin. 19 . The non-transitory computer-readable medium of claim 15 , wherein the predetermined value of ERBB2 mRNA is 7.6.
Mammography; Breast · CPC title
Cell structures in vitro; Tissue sections in vitro · CPC title
Image fusion; Image merging · CPC title
using two or more images, e.g. averaging or subtraction · CPC title
Salient features, e.g. scale invariant feature transforms [SIFT] · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.